Aurora Cannabis

What it is

Aurora Cannabis Inc. is a Canadian licensed producer headquartered in Edmonton, Alberta. It was incorporated in 2013 and received its first cultivation licence under Canada's medical cannabis framework in 2014 ^[1]. The company sells dried flower, pre-rolls, vapes, oils, softgels, and other cannabis products under several house brands, and is one of a small group of Canadian operators with the regulatory footprint to ship medical cannabis to multiple international markets ^[1][2].

Aurora trades publicly on the Toronto Stock Exchange and the Nasdaq under the ticker ACB ^[1]. Like most large Canadian LPs, it operates under licences issued by Health Canada under the Cannabis Act and the Cannabis Regulations ^[3].

Ownership and corporate structure

Aurora Cannabis Inc. is the parent company; it is not owned by a larger conglomerate. It is widely held public stock with no single controlling shareholder disclosed in its public filings ^[1].

The company has grown largely by acquisition. Notable deals include:

• MedReleaf (2018), a roughly C$3.2 billion all-stock acquisition that gave Aurora additional Ontario production and the MedReleaf medical brand ^[4].
• Whistler Medical Marijuana Corporation (2019), a smaller craft/organic-focused producer in British Columbia ^[5].
• Bevo Farms (controlling stake, 2022), a propagation and orchid/vegetable nursery business that diversified Aurora outside cannabis ^[1].

Several other acquisitions from the 2017–2019 boom have since been written down or wound down as part of post-legalization restructuring ^[6].

Market and category focus

Aurora has explicitly pivoted toward medical cannabis as its strategic priority, in contrast to peers that lean on Canadian adult-use retail ^[1][6]. The company reports medical cannabis as the majority of its net revenue, with significant volume coming from international medical exports to countries including Germany, Australia, the United Kingdom, and Poland ^[1][2].

In Canada, Aurora sells to:

• Medical patients directly via its online medical platform.
• Adult-use (recreational) markets through provincial wholesalers, under several brand names.

Internationally, products are shipped under EU-GMP certification where required for medical distribution ^[2]. Readers should not assume a product available in one country is legally available in another — international cannabis trade is tightly restricted by import permits and national regulators.

Notable brands and products

Aurora's brand portfolio has shifted over time as the company has rationalized SKUs. As of the most recent checks, brands associated with Aurora include ^[1][6]:

• Aurora and Aurora Drift — flagship medical and value-tier lines.
• MedReleaf — medical brand inherited from the 2018 acquisition.
• San Rafael '71 — a flower-focused recreational brand.
• Whistler Cannabis Co. — craft/organic-positioned brand from the BC operation.
• Daily Special — value-tier recreational line.
• Greybeard — Canadian recreational brand introduced in the early 2020s.

This page does not recommend specific products. Cannabinoid content, terpene profile, and availability of a given SKU change between batches and provinces, and 'craft' or 'organic' positioning is a marketing description, not a regulatory certification under Canadian cannabis rules.

Reputation, awards, and caveats

Aurora has won category awards at Canadian Cannabis Awards and similar trade competitions over the years for individual cultivars and brands Weak / limited. Trade awards in cannabis are voted on by industry participants and consumers, not by independent scientific panels, so they are best read as popularity and marketing indicators rather than quality certifications.

Financially, Aurora has been one of the most volatile of the large Canadian LPs. Following Canadian legalization in 2018, the company recorded major goodwill impairments and net losses, executed multiple reverse stock splits, and went through several rounds of layoffs and facility closures as part of a 'business transformation plan' ^[6][7]. Reporting from outlets such as MJBizDaily and Reuters has covered both the strategic pivot to medical and the heavy historical losses ^[6][7].

Controversies and regulatory issues

Verifiable issues include:

• Write-downs and shareholder losses. Aurora has booked billions of dollars in cumulative impairments and net losses since 2019, and shareholders have experienced large drawdowns from peak valuations ^[6][7].
• Facility closures. The company shut down or sold several Canadian facilities (including Aurora Sun, Aurora Sky scaling-back, and Polaris) as part of restructuring ^[6].
• Executive turnover. Founders and senior executives, including long-time CEO Terry Booth, departed during the post-2019 restructuring ^[7].

We are not aware of confirmed major Health Canada enforcement actions resulting in suspension of Aurora's core licences as of the last check. Always confirm current licence status directly on Health Canada's list of authorized cannabis licence holders ^[3].

Availability and legal-market notes

Aurora products are sold in Canada through provincial cannabis distributors and its medical platform. Outside Canada, Aurora supplies medical cannabis to pharmacies and distributors in jurisdictions where it holds the required import/export permissions, such as Germany and Australia ^[1][2].

Aurora is not licensed to sell cannabis in the United States; THC-containing products cannot legally cross the Canada–US border ^[3]. Any website claiming to ship Aurora THC flower into the US should be treated as a red flag.

In legal markets, patients typically need a medical authorization from a healthcare practitioner to access Aurora's medical channel.

What to verify before relying on brand claims

Before making decisions based on Aurora marketing, packaging, or third-party summaries (including this one), check:

1. Current licence status on Health Canada's authorized licence holder list ^[3].
2. The specific SKU's COA / lot information, including cannabinoid content and pesticide testing, via the QR code or batch number on the package.
3. Local availability through your provincial cannabis retailer or, for medical patients, the official Aurora medical site in your country.
4. International legality — patient access laws in Germany, Australia, the UK, Poland, and others change frequently. Do not assume yesterday's rules still apply.
5. Financial claims (revenue, market share, 'largest exporter') against Aurora's most recent quarterly filing on SEDAR+ or the SEC, rather than press releases ^[1].

Profile last checked: 2025.

Sources

How this page was made